250 related articles for article (PubMed ID: 12404703)
1. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
Oades RD; Klimke A; Henning U; Rao ML
Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703
[TBL] [Abstract][Full Text] [Related]
2. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment.
Cai HL; Fang PF; Li HD; Zhang XH; Hu L; Yang W; Ye HS
Psychiatry Res; 2011 Jul; 188(2):197-202. PubMed ID: 21146875
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics and the relevance of glutamate and serotonin.
van der Heijden FM; Tuinier S; Fekkes D; Sijben AE; Kahn RS; Verhoeven WM
Eur Neuropsychopharmacol; 2004 May; 14(3):259-65. PubMed ID: 15056486
[TBL] [Abstract][Full Text] [Related]
4. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
5. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
[TBL] [Abstract][Full Text] [Related]
6. [Catecholamine and indoleamine metabolism in groups of patients with paranoid and simple forms of schizophrenia].
Gamaleia NB
Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(5):700-8. PubMed ID: 6168149
[TBL] [Abstract][Full Text] [Related]
7. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
Schulz E; Remschmidt H; Fleischhaker C
Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
[TBL] [Abstract][Full Text] [Related]
8. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
9. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
11. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
12. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
13. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
14. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.
Alexander M; Rothman RB; Baumann MH; Endres CJ; Brasić JR; Wong DF
Synapse; 2005 May; 56(2):94-9. PubMed ID: 15729739
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients.
Mitani H; Shirayama Y; Yamada T; Kawahara R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):531-4. PubMed ID: 16414168
[TBL] [Abstract][Full Text] [Related]
16. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
17. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
18. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
Broderick PA; Olabisi OA; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
[TBL] [Abstract][Full Text] [Related]
19. Levels of biogenic amines, their metabolites, and tyrosine hydroxylase activity in the human epileptic temporal cortex.
Pintor M; Mefford IN; Hutter I; Pocotte SL; Wyler AR; Nadi NS
Synapse; 1990; 5(2):152-6. PubMed ID: 1968684
[TBL] [Abstract][Full Text] [Related]
20. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?
Jacobsen JP; Rodriguiz RM; Mørk A; Wetsel WC
Neuroscience; 2005; 132(4):1055-72. PubMed ID: 15857710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
